Tuesday, May 12, 2015 - Attorneys handling Xarelto lawsuits for clients nationwide say bellweather trials for the case are now being discussed in the Xarelto litigation underway in U.S. District Court in Louisiana. According to court documents, the scheduling of these important precedent-setting cases is dependent on decisions made regarding the discovery process: "The parties are discussing the scope of discovery, especially the length and breadth of document production, which will influence the setting of the date of the first bellweather trial," reads Case Management Order 1, which was filed on May 4, 2015.
Xarelto lawsuits have been filed by and behalf of persons throughout the United States who suffered severe internal bleeding they allege is linked to the drug Xarelto, according to court documents. The anti-coagulant thins the blood in order to prevent strokes and cardiac events, but has no known antidote to stop bleeding once it begins, according to court documents. More than 400 cases have already been consolidated in U.S. District Court in Louisiana, making common allegations, according to court documents. The Xarelto lawsuits allege that the drug makers Bayer and Johnson & Johnson did not adequately warn consumers of serious health risks associated with the drug. Furthermore, plaintiffs claim Xarelto was promoted as superior to warfarin, which they assert is false, according to court documents.
In the most recent Xarelto lawsuit news, court documents reveal that approximately 40-60 plaintiffs will be identified for in-depth examination during discovery; then, from this pool, bellweather cases will be chosen. The selection of these cases for discovery will be proposed in Case Management Order 2, which is expected to be filed by the end of June, 2015, according to the first case management order.
"The selection of cases for discovery is an important first step toward establishing bellweather trials, signaling that the case is moving forward expediently. Bellweather trials are extremely important; the outcome of these cases set the precedent for how all the other Xarelto lawsuits in this multidistrict litigation will be resolved. Making sure that the initial cases selected for discovery are representative of the scope of the allegations within the 402 cases currently pending is vital," explained Jim Onder, an experienced pharmaceutical safety litigator representing the Onder Law Firm.
The Onder Law Firm is renowned for its achievements in product and consumer safety litigation, with a strong track record of winning meaningful settlements for clients. The firm is nationally-renowned for its work on window blind strangulation, and has notable expertise in fighting on behalf of individuals against powerful corporations. Individuals and the family members of individuals who have suffered from internal bleeding and have taken Xarelto are eligible for a no-cost, no-obligation Xarelto lawsuit case review, and may contact the firm through its Xarelto Contingency Lawsuit website. The firm provides information on bleeding warnings and Xarelto lawsuit news.
The Onder Law Firm also welcomes Xarelto lawsuit inquiries from other law firms, either to handle these inquiries or work as co-counsel.
About The Onder Law Firm
Onder, Shelton, O‘Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O‘Leary & Peterson has represented clients throughout the United States, and other firms throughout the nation often seek its experience and expertise on complex litigation. It is a recognized leader in products liability cases such as window blind cord strangulation and pharmaceutical litigation. The Onder Law Firm‘s Xarelto attorneys provide information to the public at www.xareltocontingencylawsuit.com.
*Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592